NCT07511647Active, not recruitingPhase 3
A Phase 3 Clinical Study of QL2106 Injection
A Multicenter, Randomized, Double-Blind, Parallel, Active-Controlled Phase 3 Clinical Study to Compare the Efficacy and Safety of QL2106 Injection to Tremfya® in Patients With Moderate to Severe Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
It is a multicenter randomized, double-blinded, parallel, positive-controlled, Phase 3 comparative study to evaluate the efficacy and safety of QL2106 injection to Tremfya® in Patients with Moderate to Severe Plaque Psoriasis. A total of 318 subjects are planned to be included and randomized at a ratio of 1:1 to receive QL2106 injection orTremfya®
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 318 (estimated)
- First submitted
- 30 Mar 2026
- Start date
- 27 May 2026
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Diseases
- Psoriasis
- NCT number
- NCT07511647
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 318
- From 27 May 2026 to the primary completion date, 30 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
Other
- Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)
Who the study is looking for
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
- Total investigator global assessment (IGA) \>=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jining No. 1 People's Hospital. Coordinator of this site? Confirm its status | Jining | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.